Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell
Y. Hu, H. Jo, W. DeGrado, J. Wang
This study shows brilacidin has broad-spectrum antiviral activity against multiple human coronaviruses by targeting both the virus and host cell heparan sulfate proteoglycans.